Sanofi, Glaxo Seek Covid-19 Vaccine Approval in Crowded Market

Sanofi SA and GlaxoSmithKline PLC said they would seek authorization for their Covid-19 vaccine, a sign that pharmaceutical companies still see an opportunity for new shots despite ebbing demand in the West.

While vaccine uptake across the West has slowed significantly after a big push by governments to inoculate their populations, some companies say new vaccines could be used as boosters, or in low- and middle-income countries. Novavax Inc., another latecomer, recently sought emergency approval from the U.S. Food and Drug Administration for its shot, which has already been authorized in the European Union.